N Alikhanova1, I Akhundova1, M Seyfaddinova1, E Mammadbayov1, V Mirtskulava2, S Rüsch-Gerdes3, R Bayramov4, J Suleymanova5, K Kremer6, A Dadu6, C D Acosta6, A D Harries7, M Dara6. 1. Scientific Research Institute of Lung Disease, Baku, Azerbaijan. 2. TADR Test & Evaluation Lead Biological Threat Reduction Program Branch of Battelle Memorial Institute, Atlanta, Georgia, USA. 3. Forsungszentrum Borstel, Borstel, Germany. 4. Lung Disease Department, Azerbaijan State Medical University, Baku, Azerbaijan. 5. World Health Organization (WHO) Country Office, Baku, Azerbaijan. 6. WHO Regional Office for Europe, Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, Health Security & Environment, Copenhagen, Denmark. 7. International Union Against Tuberculosis and Lung Disease, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK.
Abstract
SETTING: Civilian population of the Republic of Azerbaijan. OBJECTIVES: To determine patterns of anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis (TB) cases, and explore their association with socio-demographic and clinical characteristics. DESIGN: National cross-sectional survey conducted in 2012-2013. RESULTS: Of 789 patients (549 new and 240 previously treated) who met the enrolment criteria, 231 (42%) new and 146 (61%) previously treated patients were resistant to any anti-tuberculosis drug; 72 (13%) new and 66 (28%) previously treated patients had multidrug-resistant TB (MDR-TB). Among MDR-TB cases, 38% of new and 46% of previously treated cases had pre-extensively drug-resistant TB (pre-XDR-TB) or XDR-TB. In previously treated cases, 51% of those who had failed treatment had MDR-TB, which was 15 times higher than in relapse cases (OR 15.2, 95%CI 6-39). The only characteristic significantly associated with MDR-TB was a history of previous treatment (OR 3.1, 95%CI 2.1-4.7); for this group, history of incarceration was an additional risk factor for MDR-TB (OR 2.8, 95%CI 1.1-7.4). CONCLUSION: Azerbaijan remains a high MDR-TB burden country. There is a need to implement countrywide control and innovative measures to accelerate early diagnosis of drug resistance in individual patients, improve treatment adherence and strengthen routine surveillance of drug resistance.
SETTING: Civilian population of the Republic of Azerbaijan. OBJECTIVES: To determine patterns of anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis (TB) cases, and explore their association with socio-demographic and clinical characteristics. DESIGN: National cross-sectional survey conducted in 2012-2013. RESULTS: Of 789 patients (549 new and 240 previously treated) who met the enrolment criteria, 231 (42%) new and 146 (61%) previously treated patients were resistant to any anti-tuberculosis drug; 72 (13%) new and 66 (28%) previously treated patients had multidrug-resistant TB (MDR-TB). Among MDR-TB cases, 38% of new and 46% of previously treated cases had pre-extensively drug-resistant TB (pre-XDR-TB) or XDR-TB. In previously treated cases, 51% of those who had failed treatment had MDR-TB, which was 15 times higher than in relapse cases (OR 15.2, 95%CI 6-39). The only characteristic significantly associated with MDR-TB was a history of previous treatment (OR 3.1, 95%CI 2.1-4.7); for this group, history of incarceration was an additional risk factor for MDR-TB (OR 2.8, 95%CI 1.1-7.4). CONCLUSION: Azerbaijan remains a high MDR-TB burden country. There is a need to implement countrywide control and innovative measures to accelerate early diagnosis of drug resistance in individual patients, improve treatment adherence and strengthen routine surveillance of drug resistance.
Authors: M Edginton; D Enarson; R Zachariah; T Reid; S Satyanarayana; K Bissell; S G Hinderaker; T Harries Journal: Public Health Action Date: 2012-03-21
Authors: S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; M Nikiforov; A Yedilbayev; J S Mukherjee; J J Furin; D J Barry; P E Farmer; M L Rich; S Keshavjee Journal: Int J Tuberc Lung Dis Date: 2006-04 Impact factor: 2.373
Authors: Souba Diandé; Lassana Sangaré; Séni Kouanda; Benoît I Dingtoumda; Adama Mourfou; Francis Ouédraogo; Issaka Sawadogo; Bayéma Nébié; Abdoulaye Gueye; Léon T Sawadogo; Alfred S Traoré Journal: Microb Drug Resist Date: 2009-09 Impact factor: 3.431
Authors: Matteo Zignol; Masoud Dara; Anna S Dean; Dennis Falzon; Andrei Dadu; Kristin Kremer; Harald Hoffmann; Sven Hoffner; Katherine Floyd Journal: Drug Resist Updat Date: 2014-02-28 Impact factor: 18.500
Authors: Beth Temple; Irene Ayakaka; Sam Ogwang; Helen Nabanjja; Susan Kayes; Susan Nakubulwa; William Worodria; Jonathan Levin; Moses Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Peter G Smith; Roy D Mugerwa; Jerrold J Ellner; Edward C Jones-López Journal: Clin Infect Dis Date: 2008-11-01 Impact factor: 9.079
Authors: Jason R Andrews; N Sarita Shah; Darren Weissman; Anthony P Moll; Gerald Friedland; Neel R Gandhi Journal: PLoS One Date: 2010-12-29 Impact factor: 3.240
Authors: G E Pfyffer; A Strässle; T van Gorkum; F Portaels; L Rigouts; C Mathieu; F Mirzoyev; H Traore; J D van Embden Journal: Emerg Infect Dis Date: 2001 Sep-Oct Impact factor: 6.883
Authors: Matteo Zignol; Anna S Dean; Natavan Alikhanova; Sönke Andres; Andrea Maurizio Cabibbe; Daniela Maria Cirillo; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Ashaque Husain; Alamdar Hussain; Nazir Ismail; Mostofa Kamal; Mikael Mansjö; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Ejaz Qadeer; Leen Rigouts; Sabine Ruesch-Gerdes; Marco Schito; Mehriban Seyfaddinova; Alena Skrahina; Sabira Tahseen; William A Wells; Ya Diul Mukadi; Michael Kimerling; Katherine Floyd; Karin Weyer; Mario C Raviglione Journal: Lancet Infect Dis Date: 2016-07-07 Impact factor: 25.071
Authors: Solomon Ali; Patrick Beckert; Abraham Haileamlak; Andreas Wieser; Michael Pritsch; Norbert Heinrich; Thomas Löscher; Michael Hoelscher; Stefan Niemann; Andrea Rachow Journal: BMC Infect Dis Date: 2016-11-21 Impact factor: 3.090
Authors: Matteo Zignol; Andrea Maurizio Cabibbe; Anna S Dean; Philippe Glaziou; Natavan Alikhanova; Cecilia Ama; Sönke Andres; Anna Barbova; Angeli Borbe-Reyes; Daniel P Chin; Daniela Maria Cirillo; Charlotte Colvin; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Alamdar Hussain; Nazir Ismail; S M Mostofa Kamal; Faisal Masood Khanzada; Michael Kimerling; Thomas Andreas Kohl; Mikael Mansjö; Paolo Miotto; Ya Diul Mukadi; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Leen Rigouts; Marco Schito; Ivita Sela; Mehriban Seyfaddinova; Girts Skenders; Alena Skrahina; Sabira Tahseen; William A Wells; Alexander Zhurilo; Karin Weyer; Katherine Floyd; Mario C Raviglione Journal: Lancet Infect Dis Date: 2018-03-21 Impact factor: 25.071
Authors: Anna S Dean; Matteo Zignol; Andrea Maurizio Cabibbe; Dennis Falzon; Philippe Glaziou; Daniela Maria Cirillo; Claudio U Köser; Lice Y Gonzalez-Angulo; Olga Tosas-Auget; Nazir Ismail; Sabira Tahseen; Maria Cecilia G Ama; Alena Skrahina; Natavan Alikhanova; S M Mostofa Kamal; Katherine Floyd Journal: PLoS Med Date: 2020-01-21 Impact factor: 11.069